ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO907

Plasma Cell Neoplasms After Renal Allograft: A Single-Center Experience

Session Information

Category: Transplantation

  • 1802 Transplantation: Clinical


  • Bhosekar, Chitra, Medical College of Wisconsin, Menomonee Falls, Wisconsin, United States
  • Chongkrairatanakul, Tepsiri, Medical College of Wisconsin, Menomonee Falls, Wisconsin, United States
  • D'Souza, Anita, Medical College of Wisconsin, Menomonee Falls, Wisconsin, United States
  • Bhasin, Bhavna, Medical College of Wisconsin, Menomonee Falls, Wisconsin, United States

Plasma cell disorders (PCD) are B-cell neoplasms that develop as a consequence of dysregulated B-cell clonal proliferation. The various types of PCD include monoclonal gammopathy of unknown significance (MGUS), multiple myeloma (MM) and monoclonal gammopathy of renal significance (MGRS). PCD and their complications can impact graft survival and other outcomes following kidney transplantation (KT). This underscores the need to investigate the natural history of PCD after KT.


Retrospective chart review was done at our institution in patients >18 years who had KT between 2008 and 2017 to identify those developing PCD after KT. Patients with a PCD before KT were excluded from the study.


Of the 711 patients who received KT, 12 (1.68%) developed PCD. Three patients developed MM, 2 developed MGRS and 7 had MGUS in the post-transplant course. The study population was predominantly male (75%). Patients in the MM group were younger (mean age 54 years, range 47-67) than those in the MGUS (mean age 57, range 39-69) and MGRS groups (mean age 80 years, range 74-86) at the time of transplant. The mean time from transplant to PCD was 2.9, 3.2 and 4.6 years respectively in the MGRS, MGUS and MM groups. Mean follow up of survivors in the study was 5.9 years. Epstein Barr virus (EBV) positivity was noted in all 3 MM patients but in 50% of MGRS and 28% of MGUS groups. The mean creatinine at last follow up was higher (2 mg/dL) in MM subjects and was similar (1.7 mg/dL) in the MGRS and MGUS groups. Induction and maintenance immunosuppressive regimens used were similar in three groups. One MM patient died 3 years after diagnosis but all other patients were alive with a functioning graft at last follow up.


We found an incidence of new PCD after KT of 1.68% over a 10-year period after KT, which is similar to the incidence of post-transplant lymphoproliferative disorder (1.5%-2%). The risk of developing MM may be higher in patients who are transplanted at a younger age though the time from transplant to diagnosis may be longer than other types of PCD. EBV status at KT may influence development of MM post-transplant suggesting a role of immunosuppression. These findings merit further examination in a larger study.